F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research

Stock Information for U.S. Well Services Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About U.S. Well Services Inc.

invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
invoX Pharma and F-star Therapeutics issue Joint Statement
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress
F-STAR THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, STCN, GRRB, and ZEN Shareholders About Its Ongoing Investigations
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.